Amgen (AMGN) Gross Margin (2009 - 2026)
Amgen's quarterly Gross Margin came in at 68.16% in Q1 2026, up 458.0% year-on-year from 12.21% in Q1 2025, and down 61.82% quarter-over-quarter from 178.54% in Q4 2025.
Amgen has reported Gross Margin for 18 years, with the latest figure at 68.16% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 458.0% year-over-year to 68.16%; the trailing twelve-month figure through Mar 2026 stood at 104.96% (up 3247.0% YoY), and the FY2025 full-year result was 96.43%, up 3490.0% from the prior year.
- Gross Margin for Q1 2026 stood at 68.16%, down from 178.54% in the prior quarter.
- The five-year high for Gross Margin was 178.54% in Q4 2025, with the low at 280.61% in Q4 2022.
- Average Gross Margin over 5 years is 60.67%, with a median of 73.84% recorded in 2023.
- Year-over-year, Gross Margin tumbled 44696 bps in 2022 and surged 34264 bps in 2023.
- Tracing AMGN's Gross Margin over 5 years: stood at 280.61% in 2022, then soared by 122 bps to 62.03% in 2023, then gained by 6 bps to 65.75% in 2024, then soared by 172 bps to 178.54% in 2025, then plunged by 62 bps to 68.16% in 2026.
- The last three Gross Margin figures came in at 68.16% (Q1 2026), 178.54% (Q4 2025), and 67.75% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 70.22% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.16% |
| Dec 31, 2025 | 178.54% |
| Sep 30, 2025 | 67.75% |
| Jun 30, 2025 | 99.16% |
| Mar 31, 2025 | 63.58% |
| Dec 31, 2024 | 65.75% |
| Sep 30, 2024 | 99.17% |
| Jun 30, 2024 | 61.42% |
| Mar 31, 2024 | 98.59% |
| Dec 31, 2023 | 62.03% |
| Sep 30, 2023 | 73.84% |
| Jun 30, 2023 | 74.05% |
| Mar 31, 2023 | 71.83% |
| Dec 31, 2022 | -280.61% |
| Sep 30, 2022 | 76.13% |
| Jun 30, 2022 | 77.10% |
| Mar 31, 2022 | 74.98% |
| Dec 31, 2021 | 166.35% |
| Sep 30, 2021 | 76.01% |
| Jun 30, 2021 | 74.92% |
| Mar 31, 2021 | 74.75% |
| Dec 31, 2020 | 74.79% |
| Sep 30, 2020 | 99.98% |
| Jun 30, 2020 | 76.02% |
| Mar 31, 2020 | 75.44% |
| Dec 31, 2019 | 78.69% |
| Sep 30, 2019 | 81.04% |
| Jun 30, 2019 | 81.84% |
| Mar 31, 2019 | 99.94% |
| Dec 31, 2018 | 99.82% |
| Sep 30, 2018 | 94.10% |
| Jun 30, 2018 | 99.67% |
| Mar 31, 2018 | 99.94% |
| Dec 31, 2017 | 99.50% |
| Sep 30, 2017 | 94.55% |
| Jun 30, 2017 | 99.89% |
| Mar 31, 2017 | 80.84% |
| Dec 31, 2016 | 99.79% |
| Sep 30, 2016 | 81.38% |
| Jun 30, 2016 | 80.82% |
| Mar 31, 2016 | 80.57% |
| Dec 31, 2015 | 158.30% |
| Sep 30, 2015 | 81.25% |
| Jun 30, 2015 | 79.16% |
| Mar 31, 2015 | 78.81% |
| Dec 31, 2014 | 77.14% |
| Sep 30, 2014 | 77.97% |
| Jun 30, 2014 | 78.16% |
| Mar 31, 2014 | 99.61% |
| Dec 31, 2013 | 144.20% |
| Sep 30, 2013 | 83.04% |
| Jun 30, 2013 | 82.92% |
| Mar 31, 2013 | 99.61% |
| Dec 31, 2012 | 30.74% |
| Sep 30, 2012 | 81.55% |
| Jun 30, 2012 | 82.10% |
| Mar 31, 2012 | 80.77% |
| Dec 31, 2011 | 76.02% |
| Sep 30, 2011 | 77.97% |
| Jun 30, 2011 | 84.54% |
| Mar 31, 2011 | 84.41% |
| Dec 31, 2010 | 140.72% |
| Sep 30, 2010 | 84.38% |
| Jun 30, 2010 | 100.00% |
| Mar 31, 2010 | 99.97% |
| Dec 31, 2009 | 139.70% |
| Sep 30, 2009 | 85.41% |
| Jun 30, 2009 | 98.65% |
| Mar 31, 2009 | 85.27% |